Roche’s Elecsys GALAD scores Receive the US FDA’s Breakthrough Device Designation for Earlier Diagnosis of Hepatocellular Carcinoma

 Roche’s Elecsys GALAD scores Receive the US FDA’s Breakthrough Device Designation for Earlier Diagnosis of Hepatocellular Carcinoma

Roche’s Elecsys GALAD scores Receives the US FDA’s Breakthrough Device Designation for Earlier Diagnosis of Hepatocellular Carcinoma

Shots:

  • The GALAD score combines gender and age with the biomarker results of the Elecsys AFP, AFP-L3 and PIVKA-II and is intended to aid diagnosis of early-stage HCC
  • The Elecsys GALAD will be the first GALAD score with regulatory approval to be used as IVD targeting the improvement in diagnostic workflows in the management of chronic liver disease
  • The Elecsys GALAD score in combination with blood-based biomarkers support clinicians by providing them accurate and timely information to make earlier interventions, thus improves patient’s outcomes and reduces the mortality rate in patients with HCC

Click here ­to­ read full press release/ article | Ref: Roche | Image: Ignition

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post